TargetBeta
TNF
tumor necrosis factor · also TNFSF2, DIF, TNF-alpha, TNFA · Tumor necrosis factor superfamily
5 programs in company-led studies act on TNF, from 5 companies: 1 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Adalimumabrule | Abbott | inhibitor | phase 4 | 1538 running | – | ChEMBL |
| Brentuximab Vedotinrule | Pfizer | – | phase 4 | 374 running | TNFRSF8 | NCIt |
| CHS-1420rule | Nanjing King-Friend Biochemical Pharmaceutical | inhibitor | phase 3 | 20 running | – | ChEMBL |
| brivekimig | Sanofi | – | phase 2 | 65 running | TNFSF4 | the company's pipeline |
| Hadlimarule | Biora Therapeutics | inhibitor | phase 1 | 11 running | – | ChEMBL |
Conditions their studies are in
- Colitis, Ulcerative, 2 programs
- Crohn Disease, 2 programs
- Hidradenitis Suppurativa, 2 programs
- Psoriasis, 2 programs
- Arthritis, Rheumatoid, 1 program
- Diabetes Mellitus, Type 1, 1 program
- Glomerulosclerosis, Focal Segmental, 1 program
- Hodgkin Disease, 1 program
- Lymphoma, Large B-Cell, Diffuse, 1 program
- Lymphoma, Large-Cell, Anaplastic, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 20, 2026Adalimumab · Abbott · phase 4 · NCT07788807
- Dec 17, 2026brivekimig · Sanofi · phase 2 · NCT06958536
- Jan 15, 2027Hadlima · Biora Therapeutics · phase 1 · NCT07849153
- Mar 31, 2028Brentuximab Vedotin · Pfizer · phase 4 · NCT06831370
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.